Arizona Tribune - Boulevard

NYSE - LSE

CMSC	-0.53%	21.93	$
BCE	-1.22%	22.92	$
RIO	-1.46%	93.74	$
GSK	1.16%	52.5	$
NGG	-0.49%	83.01	$
RBGPF	5.69%	65	$
CMSD	-0.73%	21.77	$
RELX	1.34%	31.34	$
RYCEF	2.12%	18.39	$
BTI	0.45%	62.76	$
BCC	1.56%	81.02	$
AZN	1.45%	188.41	$
VOD	0.22%	13.89	$
JRI	1.64%	12.79	$
BP	-1.59%	37.13	$

Featured

Cape Verde, Africa's outlier in LGBTQ tolerance

Cape Verdean make-up artist Leonardo put the finishing touches to a singer's look at a shoot for a music video, open and comfortable about being a gay man in Africa.

Israelis, Palestinians torn over sacred shrine in city of Hebron

For Israeli settler Nitzan, Hebron's Old City and its sacred Cave of the Patriarchs shrine are a must-see for all of humanity, but for Palestinian Issa Amro, it has become a symbol of Israel's expanding grip on the city.

Last news

NHI Announces First Quarter 2025 Dividend

MURFREESBORO, TN / ACCESS Newswire / February 25, 2025 / National Health Investors, Inc. (NYSE:NHI) announced today that it will pay its first quarter dividend of $0.90 per common share on May 2, 2025 to stockholders of record as of March 31, 2025.

NHI Issues Investor Update

MURFREESBORO, TN / ACCESS Newswire / February 25, 2025 / National Health Investors, Inc. (NYSE:NHI) has issued the following investor update which can be found at:

NHI Announces Fourth Quarter 2024 Results

MURFREESBORO, TN / ACCESS Newswire / February 25, 2025 / National Health Investors, Inc. (NYSE:NHI) announced today its results for the three and twelve months ended December 31, 2024.

Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in Orlando

BOULDER, CO / ACCESS Newswire / February 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it will be exhibiting at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, March 7-11, 2025.

CGFNS International to Change Its Name to TruMerit

Rebranding heralds greater focus on building a future-ready global healthcare workforce

TPT Global Tech Launches First Super App in the United States With VuMe Live

TPT Global Tech Launches First Super App in the United States with VüMe Live

Specialty Coffee Expo to Feature the World Coffee Roasting Championship During Flagship Event April 25-27 In Houston, TX

Other Competitions Include Coffee Design Awards and Best New Product Awards

Revolutionizing Mental Health: AI-Powered Facial Screening Technology Set for Clinical Trials

Synbio International Inc. secures rights to conduct clinical trials for AI-powered depression screening technology (NIMS: Non-invasive Mental Screening).NIMS is a fast, highly accurate and cost-effective method for detecting depressive symptoms through facial analysis.NIMS software is integrated into an app, that analyzes facial features from high-definition images captured by a mobile phone or desktop device.The clinical trials will assess NIMS's accuracy, reliability, and scalability for widespread use.Successful trial results will support regulatory approval, paving the way for Synbio to integrate NIMS into clinical and corporate settings.

viemaa Revolutionizes Hair Care with a Patented Biomimetic Cuticle Technology

Innovative hair care brand merges science with style to formulate products that repair and strengthen all hair types, and empower women with confidence, self-expression, and noticeably healthy hair.

StimCell Energetics Partners With ADM Tronics to Redesign eBalance Microcurrent Device for Home Use

Innovative Redesign Brings Smaller, Cost-Effective Unit with Advanced Diagnostics to Consumers

Xebra Brands Unveils Strategic 2025 Roadmap to Accelerate Growth in North American CBD Market

VANCOUVER, BC / ACCESS Newswire / February 25, 2025 / Xebra Brands Ltd. ("Xebra" or the "Company") (CSE:XBRA)(OTCQB:XBRAF)(FSE:9YC0) is pleased to announce the development of the Strategic 2025 Roadmap, a comprehensive commercial growth plan designated to expand its footprint in the North American CBD market. Developed in collaboration with a consulting firm specializing in Cannabis and CBD, the Strategic 2025 Roadmap outlines a clear roadmap to drive accelerated growth and market penetration. This strategic initiative positions Xebra to capitalize on emerging opportunities and strengthen its competitive presence in the rapidly evolving CBD industry.

Dolphin Subsidiary the Door Announces Major Roster of Chef and Lifestyle Talent for 2025 Showcasing Its Prowess for Culinary Launches and Brand Expansion

NEW YORK, NY / ACCESS Newswire / February 25, 2025 / The Door, a subsidiary of Observer's 2025 Agency of The Year Dolphin (NASDAQ:DLPN) and a leader in culinary and lifestyle PR and integrated marketing, is expanding its line up of chef and lifestyle talent for 2025. Known for representing and marketing some of the most prominent hospitality entities, culinary icons, and food and beverage consumer brands-this latest group of clients further solidifies The Door's expertise in guiding chefs and lifestyle figures through successful brand expansions such as cookbooks, restaurants and strategic partnerships.

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis

- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -- The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for the treatment of axillary hyperhidrosis -- The Company also has an issued patent in Japan covering their DMT410 program for the treatment of hyperhidrosis -

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is completeTest results support the next development step with Phase 1clinical trial expected to commence in AprilProvides Summary of Expected 2025 Milestones

CTT Pharma Gives Update On U.S. and European Patents

TAMPA, FL / ACCESS Newswire / February 25, 2025 / CTT Pharmaceutical Holdings, Inc. (OTC PINK:CTTH) has received notification of an intention to grant from the European Patent Office(EPO) for additional claims to our original European Patent. CTT Pharma already received an intention to grant from the EPO for our micelle delivery but opted to further define and strengthen our patent for diabetes related drugs. Since, the patent for the diabetes drug Liraglutide has expired CTT will seek to find opportunities to utilize our micelle technology for Liraglutide. CTT also believes our technology could offer an enhanced drug delivery system for pharmaceutical companies with current diabetes drugs that are patented and for drugs in development. Furthermore, CTT is actively working on strengthening our patents in the United States and Europe and will look to file provisional patents in 2025 to continue to protect and strengthen our technology. CTT will update shareholders on additional provisional patents once they are filed and how they will be used to help with future development.

Forte Group Closes Strategic Initiatives to Strengthen Financial Position

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES

Moderna to Present at Upcoming Conferences in March 2025

CAMBRIDGE, MA / ACCESS Newswire / February 25, 2025 / Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences:

LFTD Partners Entering Marijuana Industry in Illinois

Plans to acquire multiple Illinois Cannabis Licenses, a lease for marijuana product manufacturing in Skokie, IL, and industrial buildings and retail businesses in Rockford, IL

DR Congo PM says 'more than 7,000 dead' in war-torn east

DR Congo's prime minister said Monday that "more than 7,000" people have been killed in the east of the country since January, when the Rwanda-backed M23 group seized two major cities.

South Carolina to carry out first US firing squad execution since 2010

A South Carolina man convicted of murdering his ex-girlfriend's parents has chosen to be put to death by firing squad next month in what would be the first such execution in the United States since 2010.

EU vows to enforce digital rules despite Trump tariff warning

The EU promised on Monday to enforce its digital rules and to defend its laws "decisively" if necessary, after US President Donald Trump threatened to slap tariffs on countries that levy digital taxes on US tech firms.

Paedophile French surgeon in sex abuse trial admits to 'hideous' acts

A former French surgeon went on trial Monday charged with raping or sexually assaulting almost 300 patients, most of them children at the time, in one of the country's largest child sex abuse cases.

Upset stomach to overdose: A child's ordeal at France abuse trial

French retiree Roland Vinet is certain his grandson Mathis would still be alive if he had never met doctor Joel Le Scouarnec as a 10-year-old with an upset stomach.

Russian court upholds French researcher's jail sentence

A Russian court on Monday upheld a three-year prison sentence for French researcher Laurent Vinatier, one of several Westerners jailed by Russia during the Ukraine offensive.

Critically-ill pope had a good night, Vatican says

Pope Francis, hospitalised in critical condition with pneumonia in both lungs, spent a peaceful night and was "resting" Monday, the Vatican said amidst global concern over the pontiff's health.

Paedophile French surgeon on trial for abusing almost 300 patients

A former surgeon is to go on trial in France on Monday charged with raping or sexually assaulting almost 300 former patients, most of them children.

All Black Caleb Clarke admits dangerous driving: NZ media

All Blacks wing Caleb Clarke said he was "extremely apologetic" Monday after admitting to dangerous driving charges, New Zealand media reported.

India's Modi uses mega Hindu festival to burnish credentials

The quest of millions seeking salvation at the world's largest religious festival has also been a golden opportunity for Indian Prime Minister Narendra Modi to burnish Hindu nationalist credentials.

Desert Oasis Healthcare Honored with Dual Accolades in 2024 Best of Desert Awards

DOHC won Best Home Health Care Services and Best Nurse/Nurse Practitioner

UniDoc - Announces Filing of Amended and Restated Interim Management Discussion and Analysis

VANCOUVER, BC / ACCESS Newswire / February 24, 2025 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company"), is issuing this news release to advise its shareholders that the Company has been subject to a continuous disclosure review by the British Columbia Securities Commission. In connection therewith, the Company has filed amended and restated management's discussion and analysis ("MD&A") for the six (6) month period ended September 30, 2024, to clarify its disclosure.

Onco-Innovations' PKNP Technology Shown in Study to Demonstrate Low Toxicity and High Safety Profile

VANCOUVER, BC / ACCESS Newswire / February 24, 2025 / Onco-Innovations Limited(CSE:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information regarding its second-generation nanoparticle formulation of Polynucleotide Kinase 3'-Phosphatase (PNKP) Compound (the "Technology"), specifically that it has demonstrated enhanced PNKP inhibitor delivery, enabling solubilization with minimal toxicity, in a June 2021 study[1] conducted by researchers at the University of Alberta, Canada. The study demonstrated that the Technology was well-tolerated, even at therapeutic doses to mice with colorectal cancer, making it a promising candidate for further research and development. This finding is highly relevant, as low toxicity indicates the potential for fewer side effects, potentially allowing for use to enhance more effective and safer treatment options.

Havertys Reports Operating Results for Fourth Quarter 2024

ATLANTA, GA / ACCESS Newswire / February 24, 2025 / HAVERTYS (NYSE:HVT) and (NYSE:HVT.A), today reported its operating results for the fourth quarter ended December 31, 2024.

Arizona Tribune - Boulevard (English)